Eli Lilly and Company
Eli Lilly and Company
Your view on LLY
Overview
What the company does, where it operates, and who runs it.
About Eli Lilly and Company
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- David A. Ricks
- Headquarters
- Lilly Corporate Center, Indianapolis, IN, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- David A. Ricks
- Headquarters
- Lilly Corporate Center, Indianapolis, IN, US
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance.
Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis.
The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Eli Lilly and Company from FRC's valuation model, read against the market price. LLY last traded at $1354.00, 44.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Eli Lilly and Company. Starting points for Eli Lilly and Company: P/E 44.3, EPS $30.92, beta 0.45 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Eli Lilly and Company. Eli Lilly and Company paid $6.69 per share over the last year — a 0.5% yield at the current $1354.00 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Eli Lilly and Company. Trailing twelve-month EPS for Eli Lilly and Company stands at $30.92. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$940.00
Median
$1,450.00
High
$1,650.00
Average target · 11 new targets in the last month, average $1,528.45
Analyst Ratings
- Strong Buy0
- Buy34
- Hold9
- Sell3
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $11.20 | $10.93 | $35.36 | $50.25 |
| Low estimate | $10.47 | $10.57 | $32.84 | $44.58 |
| High estimate | $12.06 | $11.47 | $36.74 | $60.06 |
| No. of analysts | 10 | 3 | 15 | 15 |
| Year-ago EPS | $7.39 | $8.26 | $22.95 | — |
| Growth | +51.5% | +32.4% | +54.1% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $24.58B | $23.62B | $91.16B | $106.76B |
| Low estimate | $23.81B | $23.02B | $89.76B | $104.03B |
| High estimate | $26.07B | $24.51B | $91.94B | $111.70B |
| No. of analysts | 8 | 3 | 16 | 20 |
| Year-ago revenue | $19.29B | $19.80B | $65.18B | — |
| Growth | +27.4% | +19.3% | +39.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, TheStreet; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Eli Lilly and Company. Eli Lilly and Company has reported as a listed company since 1972. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Eli Lilly and Company valued side by side against its closest peers. Eli Lilly and Company is measured against Drug Manufacturers - General peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Eli Lilly and Company, and how their positions are changing. At a $1.27T market value, institutional positions materially move Eli Lilly and Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Eli Lilly and Company executives and directors. Shares of Eli Lilly and Company have traded between $623.78 and $1040.72 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Eli Lilly and Company. Eli Lilly and Company is a $1.27T Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Eli Lilly and Company. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Eli Lilly and Company. Coverage tracks Eli Lilly and Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Eli Lilly and Company.